Breaking News Instant updates and real-time market news.

ACAD

Acadia

$25.56

-0.72 (-2.74%)

, BIIB

Biogen

$229.39

-2.17 (-0.94%)

04:55
07/18/19
07/18
04:55
07/18/19
04:55

Alzheimer's Association to hold a conference

Alzheimer's Association International Conference 2019: AAICgreater than19 will be held in Los Angeles, CA on July 14-18.

ACAD

Acadia

$25.56

-0.72 (-2.74%)

BIIB

Biogen

$229.39

-2.17 (-0.94%)

CRL

Charles River

$135.30

0.08 (0.06%)

DGX

Quest Diagnostics

$100.18

-1.28 (-1.26%)

ESALY

Eisai

$0.00

(0.00%)

PKI

PerkinElmer

$95.10

-0.24 (-0.25%)

RHHBY

Roche

$0.00

(0.00%)

MRK

Merck

$81.93

0.36 (0.44%)

NSTG

NanoString

$30.44

-0.06 (-0.20%)

PRAH

PRA Health

$98.05

-0.43 (-0.44%)

QTRX

Quanterix

$31.45

0.37 (1.19%)

SYNH

Syneos Health

$47.64

-1.07 (-2.20%)

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 09

    Sep

  • 13

    Sep

  • 16

    Sep

  • 20

    Sep

  • 02

    Oct

  • 04

    Nov

ACAD Acadia
$25.56

-0.72 (-2.74%)

02/27/19
PIPR
02/27/19
NO CHANGE
Target $30
PIPR
Overweight
Acadia price target raised to $30 from $25 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $30 following the company's Q4 results. The analyst expects Nuplazid' "modest" revenue growth to continue as safety concerns "slowly subside." She also anticipates a beneficial impact to 2019 sales from the ongoing direct-to-consumer campaign. As such, the company's fiscal 2019 guidance of $275M-$300M "appears in line and readily achievable," Brill tells investors in a post-earnings research note. With Acadia beginning two Phase 3 major depressive disorder trials in the first half of 2019, the analyst expects the shares to start reflecting value for the indication as the program continues to advance. She introduced probability-adjusted numbers at a 25% chance of success into her model and keeps an Overweight rating on Acadia.
02/27/19
ADAM
02/27/19
NO CHANGE
Target $27
ADAM
Hold
Canaccord says Acadia shares 'getting interesting,' raises price target to $27
Canaccord analyst Sumant Kulkarni said Acadia reported decent Q4 results, with Nuplazid sales coming in in-line with expectations. The outlook was solid, suggesting the media issues the drug faced are behind it, which is encouraging, said Kulkarni. With that out of the way, the analyst believes the stock is getting more interesting heading into data readouts for the company's dementia and schizophrenia drugs. Kulkarni maintained his Hold rating and raised his price target to $27 from $23 on Acadia shares.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia price target raised to $35 from $30 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target on Acadia to $35 and kept her Overweight rating after its better than expected Q1 sales of Nuplazid that was driven by "accelerated growth in new patient starts." The analyst further cites the management's increased FY19 Nuplazid midpoint sales guidance and also sees "significant unrealized value" for the company's dementia related psychosis programs.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia risk/reward favorable into Phase 3 Enhance data, says Piper Jaffray
Piper Jaffray analyst Danielle Brill believes shares of Acadia Pharmaceuticals offer a favorable risk/reward into the Phase 3 Enhance trial of adjunctive Nuplazid for schizophrenia, which are expected by mid-2019. The analyst's level of conviction for a positive trial outcome remains low, but she believes investor expectations are also low and do not think the opportunity is currently reflected in Acadia's share value. She sees upside potential of 30%-35% on positive data with downside capped at 10% on a negative outcome. Brill keeps an Overweight rating on the shares with a $35 price target.
BIIB Biogen
$229.39

-2.17 (-0.94%)

05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
06/28/19
06/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating. 2. Biogen (BIIB) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term." 3. Live Nation (LYV) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying he still likes the company's growth prospects and "consistent" operating performance. 4. Arrowhead (ARWR) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Elemer Piros saying he views the stock as fairly valued. 5. Darden (DRI) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/19
STPT
06/05/19
UPGRADE
STPT
Buy
Biogen upgraded to Buy from Hold at Standpoint Research
CRL Charles River
$135.30

0.08 (0.06%)

04/02/19
WOLF
04/02/19
INITIATION
Target $146
WOLF
Peer Perform
Charles River initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Charles River with a Peer Perform and $146 price target citing relative valuation.
06/10/19
LEER
06/10/19
INITIATION
Target $155
LEER
Outperform
Charles River initiated with an Outperform at SVB Leerink
SVB Leerink analyst David Larsen initiated Charles River with an Outperform rating and $155 price target.
04/30/19
EVER
04/30/19
INITIATION
Target $160
EVER
Outperform
Charles River resumed with an Outperform at Evercore ISI
Evercore ISI resumed coverage on Charles River with an Outperform and $160 price target.
02/14/19
RHCO
02/14/19
NO CHANGE
Target $151
RHCO
Buy
Charles River price target raised to $151 from $130 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Charles River to $151 and kept his Buy rating after its "solid Q4 results" and "robust" 2019 guidance. The analyst sees positive momentum for the stock in 2019 from accelerating demand in biotech funding, adding that the lack share repurchases in 2018 and this year gives the management "ample investment & reinvestment opportunities that are being pursued by the company".
DGX Quest Diagnostics
$100.18

-1.28 (-1.26%)

07/15/19
ROTH
07/15/19
NO CHANGE
Target $7.5
ROTH
Buy
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
Roth Capital analyst Darren Aftahi notes that privately-held Sharecare, which he estimates Remark Holdings (MARK) owns about 4.5% of, recently announced Quest Diagnostics (DGX) as its preferred laboratory partner, with Quest also making a strategic investment in the company. The analyst believes this could set the stage for a potential IPO going forward. Based on his current analysis, Aftahi thinks Remark's stake is worth about $150M-$175M, implying about $3.65-$4.31/share, multiples of its current $43M value. A liquidity event in Sharecare would help to much better capitalize Remark's AI business, he contends. The analyst reiterates a Buy rating and $7.50 price target on Remark's shares.
07/15/19
GSCO
07/15/19
DOWNGRADE
Target $85
GSCO
Sell
Goldman Sachs downgrades Quest Diagnostics to Sell, cuts target to $85
Goldman Sachs analyst Patrick Donnelly downgraded Quest Diagnostics (DGX) to Sell from Neutral and lowered his price target for the shares to $85 from $90. The company remains in a flat- to low-single-digit organic growth environment which will constrain operating profit and free cash flow growth, Donnelly tells investors in a research note. Further, the analyst sees "little reason for optimism" in the near term around the UnitedHealth (UNH) Preferred Lab Network. The incentive structure to further narrow lab use is uncertain and "in-network" status is most likely to continue to dominate volume flow, says Donnelly. He sees downside risk to Quest's to out-year estimates "as the lab business struggles to grow organically."
07/15/19
GSCO
07/15/19
DOWNGRADE
Target $85
GSCO
Sell
Quest Diagnostics downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly downgraded Quest Diagnostics to Sell from Neutral and lowered his price target for the shares to $85 from $90. The analyst sees a "challenging" setup for the shares amid "muted" Preferred Lab Network prospects.
06/25/19
DBAB
06/25/19
NO CHANGE
DBAB
Deutsche says presidential order potential long-term positive for national labs
Deutsche Bank analyst Dan Leonard said he believes the presidential executive order mandating greater healthcare price transparency could be potentially neutral in the short-term and "slightly positive" in the long-term for the national labs, LabCorp (LH) and Quest Diagnostics (DGX). He keeps a Buy rating on LabCorp and Hold rating on Quest shares.
ESALY Eisai
$0.00

(0.00%)

08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
03/22/19
NOMU
03/22/19
DOWNGRADE
NOMU
Reduce
Eisai downgraded to Reduce from Buy at Nomura Instinet
Nomura Instinet analyst Motoya Kohtani double downgraded Eisai to Reduce from Buy and lowered his price target for the shares to 6,000 yen from 17,000 yen following the cancellation of the Phase 3 trial of aducanumab. The analyst said he had high expectations for the drug.
03/21/19
COWN
03/21/19
NO CHANGE
Target $275
COWN
Outperform
Biogen price target cut to $275 from $400 at Cowen
Cowen analyst Philip Nadeau cut his price target for Biogen (BIIB) to $275 from $400 after the company and its partner Eisai (ESALY) announced that the Phase 3 ENGAGE and EMERGE studies of aducanumab for the treatment of cognitive impairment and dementia in Alzheimer's disease will be stopped for futility. The analyst maintains an Outperform rating.
03/22/19
SBSH
03/22/19
DOWNGRADE
SBSH
Sell
Eisai downgraded to Sell from Neutral at Citi
Citi analyst Hidemaru Yamaguchi downgraded Eisai to Sell from Neutral.
PKI PerkinElmer
$95.10

-0.24 (-0.25%)

04/09/19
04/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Market Perform at Cowen with analyst Doug Creutz saying he views Disney's "catalyst path for the next year as highly attractive" and believes Thursday's investor day will likely be a "deck-clearing event for sentiment." 2. Comcast (CMCSA) upgraded to Outperform from Neutral at Macquarie with analyst Amy Young saying she remains bullish on pure-play Altice and efforts across Sky, Xfinity, and NBCU. 3. Geron (GERN) upgraded to Buy from Hold at Needham with analyst Chad Messer saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity." 4. Public Storage (PSA) upgraded to Hold from Underperform at Jefferies with analyst Omotayo Okusanya saying with interest rates set to be lower for longer, equity risk premiums have dropped. 5. PerkinElmer (PKI) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying the continuation of the company's growth acceleration should exceed "conservative" expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/19
GSCO
04/09/19
UPGRADE
GSCO
Conviction Buy
Goldman sees growth acceleration for PerkinElmer, upgrades to Conviction Buy
Goldman Sachs analyst Patrick Donnelly upgraded PerkinElmer to Buy from Neutral and added the shares to his firm's Conviction List. He upped his price target for the stock to $115 from $92. The analyst sees 2019 as a continuation of the growth acceleration seen in 2018 "with overly conservative" guidance and with consensus estimates "largely mirroring management expectations." PerkinElmer's Diagnostics business has a path to 10%-12% organic growth, driving the company's organic growth level to among the best in Tools, Donnelly tells investors in a research note. He believes consensus expectations are currently "underappreciating the conservatism" built into the core PerkinElmer business.
04/09/19
GSCO
04/09/19
UPGRADE
Target $115
GSCO
Conviction Buy
PerkinElmer upgraded to Conviction Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly upgraded PerkinElmer to Buy from Neutral and added the shares to his firm's Conviction List. He upped his price target for the stock to $115 from $92. The continuation of the company's growth acceleration should exceed "conservative" expectations, Donnelly tells investors in a research note.
05/30/19
WOLF
05/30/19
INITIATION
Target $97
WOLF
Peer Perform
PerkinElmer initiated with a Peer Perform at Wolfe Research
Wolfe Research started PerkinElmer with a Peer Perform rating and $97 price target.
RHHBY Roche
$0.00

(0.00%)

06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
MRK Merck
$81.93

0.36 (0.44%)

07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
NSTG NanoString
$30.44

-0.06 (-0.20%)

09/13/18
JPMS
09/13/18
NO CHANGE
Target $20
JPMS
Overweight
NanoString price target raised to $20 from $17 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for NanoString to $20 after hosting a dinner with management. The analyst came away "impressed" at the degree of customer interest in digital spatial profiling, now branded GeoMx, ahead of commercial launch in the first half of 2019. He cites management's "bullish tone around the launch" for his target bump and keeps an Overweight rating on NanoString.
10/09/18
UBSW
10/09/18
INITIATION
Target $23
UBSW
Buy
NanoString initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated NanoString with a Buy rating and $23 price target.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
03/08/19
JPMS
03/08/19
NO CHANGE
Target $35
JPMS
Overweight
NanoString price target raised to $35 from $20 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for NanoString to $35 saying the company reported "strong" Q4 results. The analyst remains encouraged by signs of continued stabilization in the core portfolio over the last few quarters and "extremely robust" early customer interest in GeoMx. He reiterates an Overweight rating on NanoString shares.
PRAH PRA Health
$98.05

-0.43 (-0.44%)

05/02/19
KEYB
05/02/19
DOWNGRADE
KEYB
Sector Weight
PRA Health downgraded to Sector Weight from Overweight at KeyBanc
05/03/19
KEYB
05/03/19
DOWNGRADE
KEYB
Sector Weight
PRA Health downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Donald Hooker downgraded PRA Health to Sector Weight from Overweight and lowered his model estimates to bake-in additional caution with respect to the performanceof the Symphony Health business that was acquired in late 2017. Revenues declined y/y and management made a change in leadership with plans to make additional investments to grow the business, Hooker tells investors in a research note, adding that he is lowering his 2020E adjusted EBITDA to $582M with a base case valuation in line now with the broader biopharma outsourcing space.
07/02/19
LEER
07/02/19
INITIATION
Target $105
LEER
Market Perform
PRA Health initiated with a Market Perform at SVB Leerink
SVB Leerink analyst David Larsen initiated PRA Health with a Market Perform and $105 price target.
06/03/19
BARD
06/03/19
NO CHANGE
Target $122
BARD
Outperform
PRA Health designated as a Fresh Pick at Baird
Baird analyst Eric Coldwell designated PRA Health as a Fresh Pick as he believes the recent selloff in the shares is overdone. The analyst said the price is now right to assume risks and look through recent concerns. He said the premium story is now trading at a discount, and he sees the shares capable of rallying back toward $100 in the near term. Coldwell reiterated his Outperform rating and $122 price target on PRA Health.
QTRX Quanterix
$31.45

0.37 (1.19%)

10/10/18
ADAM
10/10/18
INITIATION
Target $27
ADAM
Buy
Quanterix initiated with a Buy at Canaccord
Canaccord analyst Mark Massaro initiated Quanterix with a Buy rating as he views it as a precision medicine pure-play. He sees the company being well positioned to disrupt the attractive life sciences research market with its ultra-high sensitive, digital, single molecule array immunoassay instrument platforms. Massaro has a $27 price target on Quanterix shares.
SYNH Syneos Health
$47.64

-1.07 (-2.20%)

03/19/19
UBSW
03/19/19
DOWNGRADE
UBSW
Neutral
Syneos Health downgraded to Neutral from Buy at UBS
04/02/19
WOLF
04/02/19
INITIATION
Target $53
WOLF
Peer Perform
Syneos Health initiated with a Peer Perform at Wolfe Research
Wolfe Research started Syneos Health with a Peer Perform rating and $53 price target, stating that while the stock trades at a meaningful discount to peers the firm doesn't have the conviction to step in given that results and stock performance to date have been highly volatile.
03/19/19
UBSW
03/19/19
DOWNGRADE
Target $55
UBSW
Neutral
Syneos Health downgraded to Neutral on SEC probe risks at UBS
As previously reported, UBS analyst Daniel Brennan downgraded Syneos Health to Neutral from Buy as the stock's implied discount versus peers has narrowed to less than 5% despite higher risks given an ongoing SEC investigation and material weaknesses now part of the 10K. The "distraction and optics" of an SEC investigation creates an opening for competitors, contends Brennan. He keeps a $55 price target on Syneos Health shares.
03/19/19
WBLR
03/19/19
NO CHANGE
WBLR
Outperform
Syneos Health discount to group 'seems excessive,' says William Blair
William Blair analyst John Kreger noted that Syneos Health released fourth quarter results that were well ahead of his expectations and gave initial 2019 guidance that was also modestly ahead of his forecasts following a delay that was prompted by an SEC investigation notice. While he believes a modest discount to the peer group is warranted, given the SEC investigation and the market view that commercial deserves a lower multiple, Kreger thinks the stock's current discount "seems excessive." He reiterates an Outperform rating on Syneos Health shares.

TODAY'S FREE FLY STORIES

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

WDC

Western Digital

$59.26

0.9 (1.54%)

, AAPL

Apple

$237.68

1.47 (0.62%)

10:39
10/14/19
10/14
10:39
10/14/19
10:39
On The Fly
Western Digital rises as analyst says buy on rising flash prices »

Shares of Western Digital…

WDC

Western Digital

$59.26

0.9 (1.54%)

AAPL

Apple

$237.68

1.47 (0.62%)

STX

Seagate

$53.60

-0.2 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 04

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

HUM

Humana

$264.13

-2.2 (-0.83%)

10:34
10/14/19
10/14
10:34
10/14/19
10:34
Hot Stocks
Humana among five MA plans selected for Florida Medicare retirees »

Humana (HUM), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 13

    Nov

EHTH

eHealth

$54.37

-1.61 (-2.88%)

10:29
10/14/19
10/14
10:29
10/14/19
10:29
Recommendations
eHealth analyst commentary  »

eHealth churn concerns…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Options
Bausch Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

GNUS

Genius Brands

$0.83

0.06 (7.79%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
Genius Brands to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

SDC

SmileDirectClub

$10.56

-0.54 (-4.86%)

10:20
10/14/19
10/14
10:20
10/14/19
10:20
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/14/19
10/14
10:17
10/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/14/19
10/14
10:16
10/14/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$6.94

-0.5 (-6.72%)

10:15
10/14/19
10/14
10:15
10/14/19
10:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PING

Ping Identity

$16.72

0.25 (1.52%)

, NVST

Envista

$27.55

-0.32 (-1.15%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PING

Ping Identity

$16.72

0.25 (1.52%)

NVST

Envista

$27.55

-0.32 (-1.15%)

DDOG

Datadog

$36.25

0.58 (1.63%)

BYND

Beyond Meat

$125.99

-5.41 (-4.12%)

BE

Bloom Energy

$3.11

-0.055 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 04

    Dec

FAST

Fastenal

$35.95

-0.41 (-1.13%)

, AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

FAST

Fastenal

$35.95

-0.41 (-1.13%)

AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

DAL

Delta Air Lines

$52.44

-0.5 (-0.94%)

TOL

Toll Brothers

$39.32

-0.17 (-0.43%)

CGC

Canopy Growth

$18.66

-0.76 (-3.91%)

HEXO

Hexo

$2.38

-0.155 (-6.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

  • 12

    Nov

NKE

Nike

$94.70

0.8 (0.85%)

, WDC

Western Digital

$59.86

1.5 (2.57%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

NKE

Nike

$94.70

0.8 (0.85%)

WDC

Western Digital

$59.86

1.5 (2.57%)

VAR

Varian Medical

$112.50

1.72 (1.55%)

XLNX

Xilinx

$96.70

0.52 (0.54%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

LK

Luckin Coffee

$18.99

-0.025 (-0.13%)

10:05
10/14/19
10/14
10:05
10/14/19
10:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVST

Envista

$27.55

-0.32 (-1.15%)

10:02
10/14/19
10/14
10:02
10/14/19
10:02
Initiation
Envista initiated  »

Envista initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$53.10

-2.88 (-5.14%)

10:01
10/14/19
10/14
10:01
10/14/19
10:01
Periodicals
eHealth lower following cautious Off Wall Street mention »

Shares of eHealth are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAFM

Sanderson Farms

$148.68

-1.2 (-0.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Conference/Events
Sanderson Farms to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.